IMS Health forecasts the global pharmaceutical market to grow 2.5%–3.5% in 2009, excluding currency effects, to more than $750 billion. This is down from the previous estimate of 4.5%–5.5% growth (see IBO 10/31/08). Compound annual growth for 2009 through 2013 is estimated to be 3%–6%. IMS observed that consumers are less likely to start new […]
FoodProcessing.com estimates that capital spending by the top 20, publicly held, US food and beverage companies will decline 2.9% this year. Eleven of the 20 firms plan to increase capital spending in 2009. In some cases, the companies are planning to do so because of acquisitions, including Ralcorp and J.M. Smucker. Of the 11 companies […]
The EPA plans to regulate greenhouse gases. Agency studies found that carbon dioxide, methane, nitrous oxide, hydrofluorocarbons, perfluorocarbons and sulfur hexafluoride are public health hazards. Source: New York Times
This year, the EPA will begin to implement the Endocrine Disruptor Screening Program (EDSP), which was established in 1998. Initially, 67 pesticide active ingredients and high-production volume chemicals used as pesticide inert ingredients will be screened. Tier 1 of the EDSP will screen the substances for interactions with estrogen, androgen or thyroid hormone systems. Substances […]
The first of IBO’s biannual new laboratory roundup focuses on the Middle East and food testing in Asia. Despite the drop in the price of oil, oil money continues to stimulate new lab growth in the Middle East. The establishment of food safety testing laboratories in Asia is a high priority for independent testing laboratories, […]
The cosmetics and personal care market is a bright spot for many chemical companies during the recession. Univar Personal, Gelest and Rhodia are among the firms that have indicated continuing demand for cosmetic and personal care products and ingredients. However, customers are switching to more cost-effective brands and products. To continue to attract customers and […]
A new report from the Centers for Disease Control and Prevention (CDC) indicates that US food safety has not improved since 2005. Sixteen of every 100,000 people had confirmed cases of salmonella in 2008, compared to 14 out of 100,000 in 2005. Although the increase may be a statistical anomaly, many foodborne illnesses, including listeria […]
In calendar year 2008, Thermo Fisher Scientific retained its position as the number one provider of analytical and life science instruments and aftermarket products, according to IBO’s annual calculation of the top 30 companies. The top 30 companies generated an estimated $26.6 billion in sales of analytical and life science instruments and aftermarket products last […]
According to a report by the US Government Accountability Office (GAO), the three federal agencies charged with detecting seafood fraud—the Department of Homeland Security’s Customs and Border Protection (CBP), the Department of Commerce’s National Marine Fisheries Service (NMFS) and the FDA—are not working together effectively. More than 80% of the five billion pounds of seafood […]
In a paper published this month, the EPA outlined its strategic plans to implement a new approach to chemical toxicity testing. Current approaches rely almost exclusively on animal testing. The new model for toxicity testing and risk assessment is focused on toxicity pathways. Information on the pathways will be combined with distributional data on population […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
